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Introduction
Prospective studies have unequivocally identified that
valproate poses an unacceptable risk to the foetus in utero,
prompting European and national bodies to issue unam-
biguous advice to neurologists. In 2014, The European
Medicines Agency recommended strengthening the
restrictions on the use of valproate in women and girls. The
joint task force of International League Against Epilepsy-
commission on European affairs and European Academy of
Neurology responded with a detailed letter, later published
in Epilepsia, which included seven recommendations. The
first of which is ‘‘Where possible, valproate should be
avoided in women of childbearing potential.’’ In January
2015, the Medicines and Healthcare products Regulatory
Agency (MHRA) in the United Kingdom issued stringent
guidance regarding the prescription of valproate to women
of child-bearing potential. The data supporting these
statements were based on robust prospective research
approximating the risk of major malformations at one in
ten, and that four in ten children are at risk of neurode-
velopmental disorders. The advice is, therefore, that first
valproate should not be used in girls or women of child-
bearing potential unless other treatments are ineffective or
not tolerated, and second that women of child-bearing
potential must use effective contraception during
treatment.
However, valproate cannot simply be discarded from the
panoply of anti-epileptic medications since it remains one
of the most efficacious therapies; especially for those
patients with genetic generalised epilepsy. In recognition of
this recent MHRA guidance states ‘‘No-one should stop
taking valproate without discussing it first with their doctor
and the benefits of valproate treatment must be carefully
balanced against the risks.’’ However, despite the advice
offered, there remains much that we do not know about
valproate and foetal outcomes. Below we discuss three
papers that aim to improve the description of risks to the
foetus of valproate exposure including foetal loss, autism
spectrum disorder and congenital malformations.
Dose-dependent teratogenicity of valproate
in mono- and polytherapy: an observational study
A consistent finding from epilepsy and pregnancy registries
is higher doses of valproate are less safe than lower doses
of valproate, and that valproate used in combination with
other drugs is more cognitively and physically teratogenic
than when used alone. For women with genetic generalised
epilepsy who need valproate for adequate seizure control
consideration should, therefore, be given as to whether a
minimum valproate dose together with an alternative
concomitant therapy or the smallest efficacious dose of
valproate in monotherapy should be used. The International
Registry of AEDs and Pregnancy (EURAP) is an obser-
vational study established in 1999 that brings together
investigators from 42 countries from Europe, Asia, Aus-
tralia, and Latin America. It primarily studies major con-
genital malformations by recruiting women prior to week
16 of pregnancy. As such, EURAP studies can often pro-
vide the largest sample seizes for sub-group comparison
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studies. This study identified 1224 pregnancies with val-
proate as monotherapy and 364 when valproate was taken
with another anti-epileptic drug; 44 % of combinations
were valproate and lamotrigine.
Major malformations, at 1 year of age, were seen in
10 % of children exposed to valproate alone, in 11.3 %
exposed to valproate and lamotrigine and in 11.7 %
exposed to valproate and another anti-epileptic drug that
was not lamotrigine. Their major finding was that it was the
dose of valproate that predicted malformation rate with
doses of over 1.5 g a day associated with a major increase:
24 % monotherapy; 31 % valproate and lamotrigine;
19.2 % valproate and another drug.
Comment: This is further evidence that the dose of
valproate matters, even more than any additional anti-
epileptic medication it may be taken with. Studies such as
this are important and laudable. However, by cleaning the
data by removing women with other concomitant drugs and
previous health problems it can be argued that these data
remain difficult to interpret in a real-world situation. Anti-
epileptic drugs are notorious for their drug–drug interac-
tions and valproate and lamotrigine interactions are clini-
cally relevant and may underlie the large proportion
malformations when a large valproate dose is prescribed
together with lamotrigine. EURAP, in keeping with many
studies, struggles to accurately classify epilepsy within this
cohort and, therefore, diagnosis-specific effects remain
unclear.
Tomson T et al (2015) Neurology 85(10):866–872.
Prospective assessment of autism traits in children
exposed to anti-epileptic drugs during pregnancy
Anecdotal reports and retrospective analyses of the cog-
nitive outcomes of children exposed to valproate in utero
have prompted more detailed epidemiological research.
However, for causality to be fully determined, adequately
powered prospective studies are needed and initial studies
that identified valproate-associated neurodevelopmental
disorders including autism, need replicating and verifying.
Wood and colleagues identified 105 children aged 6–8 via
the Australian Pregnancy Register for Women on
Antiepileptic Medication. They used a rating scale to
estimate the level of autistic traits in these children and
determined that children who scored above a certain cutoff
displayed ‘autistic traits’.
Valproate exposure, and in particular higher doses of
valproate, was significantly associated with autistic traits in
the children studied. 10.5 % demonstrated autistic trai-
ts—of these, all bar two were exposed to valproate, and
64 % were taking valproate as part of a polytherapy
regimen. In total, 47 % of women who took valproate
alongside one or more anti-epilepsy drug had children with
autistic traits. Further analyses identified that women who
did not take folic acid supplements in the first trimester and
those who smoked marijuana, were both more likely to
have children who demonstrated autistic traits.
Comment: Children with autistic traits in this study were
exposed to valproate doses of between 1 and 3 g/day,
mostly in combination with other anti-epilepsy drugs. This
study was able to identify and control for factors such as
maternal IQ, the type of epilepsy and seizure severity in
pregnancy. The sample size and study design were not
sufficient for polytherapy combinations to be analysed. In
the discussion, the authors report that a number of mothers
of children who had high scores on the rating scale, also
had further children with autism diagnoses. They postulate
that an as yet unproven genetic susceptibility may confer
some of the autistic trait risk seen in this study.
Wood AG et al (2015) Epilepsia 56(7):1047–1055.
Anti-epileptic drugs and intrauterine death:
a prospective observational study from EURAP
The pregnancy must come to term for pregnancy outcomes
such as malformations and autism to be studied. Most
major teratogens also cause intrauterine death. This study
was prompted by a Danish registry paper that failed to find
a link between anti-epileptic drugs and spontaneous abor-
tion in all women, but did when women with epilepsy were
concerned. Using the EURAP registry (described above)
the authors identified 7055 eligible pregnancies in 6146
women. There were 592 spontaneous abortions (8.4 %) and
40 stillbirths (0.6 % of pregnancies). No single drug at any
dose was associated with an increased risk; however, the
rate of intrauterine death was higher in foetuses exposed to
polytherapy (12.1 %). Other factors identified would be
expected to increase the intrauterine death rate in all
cohorts studied: maternal age; parental congenital malfor-
mation; prior intrauterine deaths.
Comment: This is a large and well-designed study which
supports clinicians in answering difficult and nuanced
questions in clinic. The major deficiency in the study is the
absence of a marker of epilepsy severity and the ability to
quantify the number of convulsive seizures that each
mother had in pregnancy. Furthermore, the EURAP
registry was unable to answer an important related ques-
tion—what is the risk to women with epilepsy and children
who are unmedicated in pregnancy? This is important as
current guidance is unanimous in stating that the risks of
seizures in pregnancy are greater than the risks of the
drugs, and that pregnant women should remain on
1888 J Neurol (2016) 263:1887–1889
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medication. Although whether this is the case for all
women, for all epilepsies, and all drugs remains unclear.
What is more certain is that when taken as a trio of papers
it becomes clear that when women of reproductive age
require anti-seizure medication, we should prescribe
monotherapy; and if it has to be valproate, then it must be
the smallest dose possible.
Tomson T et al (2015) Neurology 85(7):580–588.
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